These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

160 related articles for article (PubMed ID: 23963218)

  • 1. Regulatory review: How do agencies ensure the quality of decision making?
    Liberti L; McAuslane N; Patel P; Breckenridge A; Eichler HG; Peterson R
    Clin Pharmacol Ther; 2013 Sep; 94(3):305-8. PubMed ID: 23963218
    [TBL] [Abstract][Full Text] [Related]  

  • 2. On the prohibition of conflicts of interest in pharmaceutical regulation: precautionary limits and permissive challenges. A commentary on Sismondo (66:9, 2008, 1909-14) and O'Donovan and Lexchin.
    Abraham J
    Soc Sci Med; 2010 Mar; 70(5):648-51. PubMed ID: 20056525
    [No Abstract]   [Full Text] [Related]  

  • 3. The innovative medicines initiative: a European response to the innovation challenge.
    Goldman M
    Clin Pharmacol Ther; 2012 Mar; 91(3):418-25. PubMed ID: 22318619
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Assessing the Quality of Decision Making in the Development and Regulatory Review of Medicines: Identifying Biases and Best Practices.
    Bujar M; Donelan R; McAuslane N; Walker S; Salek S
    Ther Innov Regul Sci; 2017 Mar; 51(2):250-256. PubMed ID: 30231720
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The Confluence of Accelerated Regulatory and Health Technology Assessment Access Pathways.
    McAuslane N; Liberti L; Connelly P
    Clin Pharmacol Ther; 2019 Apr; 105(4):935-942. PubMed ID: 30472729
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Quality of Regulatory Decision-Making Practices: Issues Facing Companies and Agencies.
    Bujar M; McAuslane N; Salek S; Walker S
    Ther Innov Regul Sci; 2016 Jul; 50(4):487-495. PubMed ID: 30227024
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Quality Decision-Making Practices in Pharmaceutical Companies and Regulatory Authorities: Current and Proposed Approaches to Its Documentation.
    Bujar M; McAuslane N; Connelly P; Walker SR
    Ther Innov Regul Sci; 2020 Nov; 54(6):1404-1415. PubMed ID: 32472442
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Interaction initiatives between regulatory, health technology assessment and coverage bodies, and industry.
    Frønsdal K; Pichler F; Mardhani-Bayne L; Henshall C; Røttingen JA; Mørland B; Klemp M
    Int J Technol Assess Health Care; 2012 Oct; 28(4):374-81. PubMed ID: 23062516
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The patients' and consumers' working party at the European Medicines Agency: a model of interaction between patients, consumers, and medicines regulatory authorities.
    Moulon I; Dedes N
    J Ambul Care Manage; 2010; 33(3):190-7. PubMed ID: 20539145
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Is there a need for a universal benefit-risk assessment framework for medicines? Regulatory and industry perspectives.
    Leong J; McAuslane N; Walker S; Salek S
    Pharmacoepidemiol Drug Saf; 2013 Sep; 22(9):1004-12. PubMed ID: 23740622
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Building Synergy between Regulatory and HTA Agencies beyond Processes and Procedures-Can We Effectively Align the Evidentiary Requirements? A Survey of Stakeholder Perceptions.
    Wang T; McAuslane N; Liberti L; Leufkens H; Hövels A
    Value Health; 2018 Jun; 21(6):707-714. PubMed ID: 29909876
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Should pharmacometrics be training the next R&D president?
    Gobburu JV
    Clin Pharmacol Ther; 2014 Jun; 95(6):579-80. PubMed ID: 24842637
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Regulatory Forum Opinion Piece
    Morgan SJ; Couch J; Guzzie-Peck P; Keller DA; Kemper R; Otieno MA; Schulingkamp RJ; Jones TW
    Toxicol Pathol; 2017 Apr; 45(3):372-380. PubMed ID: 28351296
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Quality of medicines: Deficiencies found by Brazilian Health Regulatory Agency (ANVISA) on good manufacturing practices international inspections.
    Geyer ARC; Sousa VD; Silveira D
    PLoS One; 2018; 13(8):e0202084. PubMed ID: 30089162
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Regulatory Capture in Pharmaceutical Policy Making: The Case of National Medicine Agencies Related to the EU Falsified Medicines Directive.
    Borup R; Traulsen JM; Kaae S
    Pharmaceut Med; 2019 Jun; 33(3):199-207. PubMed ID: 31933284
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Limits to neoliberal reforms in the health sector: the case of pharmaceutical management in New Zealand.
    Dew K; Davis A
    Int J Health Serv; 2014; 44(1):137-53. PubMed ID: 24684088
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Quality Decision Making in Health Technology Assessment: Issues Facing Companies and Agencies.
    Bujar M; McAuslane N; Walker SR; Salek S
    Ther Innov Regul Sci; 2020 Mar; 54(2):275-282. PubMed ID: 32072598
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Characterizing Good Review Practices: A Survey Report Among Agencies of APEC Member Economies.
    Liu LL; McAuslane N; Tzou MC; Chern HD; Liberti L; Ward M; Kang JJ
    Ther Innov Regul Sci; 2013 Nov; 47(6):678-683. PubMed ID: 30235555
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Regulation and Innovation: Role of Regulatory Science in Facilitating Pharmaceutical Innovation.
    Honig P; Zhang L
    Clin Pharmacol Ther; 2019 Apr; 105(4):778-781. PubMed ID: 30883715
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Data Integrity-A Study of Current Regulatory Thinking and Action.
    Shafiei N; De Montardy R; Rivera-Martinez E
    PDA J Pharm Sci Technol; 2015; 69(6):762-70. PubMed ID: 26659106
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.